ArticleEnvironmental health insights2016
Small-Scale Trials Suggest Increasing Applications of Natular™ XRT and Natular™ T30 Larvicide Tablets May Not Improve Mosquito Reduction in Some Catch Basins.
Article in Environmental health insights, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stormwater catch basins are commonly treated with larvicides by mosquito control agencies to reduce local populations of mosquito species capable of transmitting West Nile virus. Recent evidence suggests that extended-release larvicides formulated to last up to 180 days in catch basins may not be effective in some basins due to chronic flushing, rapid dissolution, or burying of treatment in sump debris. To investigate if increasing the number of applications could improve effectiveness, a small study was performed over 13 weeks in 2015 to evaluate two extended-release larvicides (Natular™ XRT 180-day tablets and Natular™ T30 30-day tablets) and a larvicide oil (CocoBear™). Over the course of 13 weeks, three groups of eight basins were monitored for mosquitoes, each group receiving Natular™ XRT, Natular™ T30, or CocoBear™ larvicides. All basins received a single application at the beginning of the study period. Once mosquitoes in a basin surpassed the treatment threshold during weekly monitoring, an additional application of the associated larvicide was given to that basin. The number of applications during the study period ranged from 1 to 10 for CocoBear™ basins, 1 to 7 for T30 basins, and 2 to 8 for XRT basins. Overall, the average number of applications and the cost of larvicide per basin were 4.4 applications at $0.66 per Coco-Bear™ basin, 4.4 applications at $6.26 per T30 basin, and 4 applications at $16.56 per XRT basin. Basins treated with XRT and T30 needed reapplications more often than expected, yet were no more effective than CocoBear™, suggesting that increasing the frequency of application of these larvicide formulations may not provide increased mosquito reduction in some basins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.